Letters

Changing face of ectopic pregnancy

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7118.1311a (Published 15 November 1997) Cite this as: BMJ 1997;315:1311

Medical treatment of ectopic pregnancy preserves reproductive potential

  1. Mehmet R Gazvani, Research fellow in reproductive medicinea,
  2. Ian Aird, Lecturer in obstetrics and gynaecologya,
  3. Simon J Wood, Research fellow in reproductive medicinesa,
  4. Angus J M Thomson, Research fellow in reproductive medicinea,
  5. Charles R Kingsland, Consultant in obstetrics and gynaecologya
  1. b University Department of Obstetrics and Gynaecology, National Women's Hospital, Epsom, Auckland, New Zealand
  2. a Liverpool Women's Hospital, Liverpool L8 7SS

    Editor—We agree with Mascarenhas et al that laparoscopic or medical treatment should now replace laparotomy in the treatment of ectopic pregnancy.1 We disagree, however, with the statement that methotrexate treatment does not seem to be a replacement for laparoscopic salpingotomy. The authors suggest that methotrexate injection may be associated with increased abdominal pain six to seven days after the treatment as well as a transient increase in human chorionic gonadotrophin titres within the first four days. They suggest that the increased titres may cause undue distress and lead to additional treatment.

    It is true that 15-20% of patients experience abdominal pain six to seven days after methotrexate treatment, but this responds to mild pain relief. The rise in titres of human chorionic gonadotrophin up to day 4 is irrelevant as protocols for methotrexate treatment take into account the titres on days 4 and 7. If the titres between days 4 and 7 drop by ≥15% then a second injection …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe